Skip to main content
Medexus Pharmaceuticals Inc. logo

Medexus Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MDP ISIN · CA58410Q2036 LEI · 8945002TBEYY0HLH1M19 TSX Manufacturing
Open in API
Filings indexed 638 across all filing types
Latest filing 2024-06-26 Regulatory Filings
Country CA Canada
Listing TSX MDP

About Medexus Pharmaceuticals Inc.

https://www.medexus.com/en_US

Medexus Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company engaged in the development and commercialization of treatment solutions. The company utilizes a highly scalable North American business model, leveraging a fully integrated infrastructure encompassing commercial operations, supply chain, regulatory affairs, and a dedicated salesforce. Medexus focuses on building a portfolio of specialty and rare disease products across key therapeutic areas, including hematology, hematology-oncology, allergy, dermatology, and rheumatology. Its mission is to deliver quality healthcare products to patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 100% confidence The document is titled 'FORM 13-502F1' and is a 'Management Certification' submitted to the Ontario Securities Commission. It contains detailed calculations of market values of securities for quarterly periods within a financial year, participation fees, and related fee payments. The content is primarily a certification by an officer regarding the accuracy and completeness of the information provided in the form. There are no financial statements, management discussion, or detailed financial results presented. The document is a regulatory filing form related to fees and market values, not a financial report or earnings release. It fits the criteria for a Regulatory Filing (RNS) as it is a certification and submission to a regulatory body without substantive financial data or report content.
2024-06-26 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 95% confidence The document is a Form 13-501F1 submission to the Alberta Securities Commission, which includes a management certification by an officer of the reporting issuer. It contains market value calculations for specified trading periods and a participation fee calculation. The document is primarily a certification and regulatory submission rather than a financial report or earnings release. It does not contain financial statements or detailed financial analysis but is a regulatory filing with certification. Therefore, it fits best under Regulatory Filings (RNS). The document length is 4583 characters, which is consistent with a certification and regulatory form rather than a full report.
2024-06-26 English
52-109F1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F1 Certification of Annual Filings by the CFO of Medexus Pharmaceuticals Inc. It certifies the review and fair presentation of the annual filings including the AIF, annual financial statements, and annual MD&A for the financial year ended March 31, 2024. The document focuses on the certification of disclosure controls and internal controls over financial reporting as required by National Instrument 52-109. It does not contain the actual annual report or financial statements but is a formal certification related to those filings. According to the rules, such officer certifications should be classified as Regulatory Filings (RNS) rather than the report itself (10-K or Annual Report). The document length is 4550 characters, which is relatively short and consistent with a certification letter rather than a full report.
2024-06-26 English
52-109F1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F1 Certification of Annual Filings Full Certificate signed by the CEO, certifying the review and fair presentation of the annual filings including the AIF, annual financial statements, and annual MD&A for the financial year ended March 31, 2024. It references the design and evaluation of disclosure controls and internal control over financial reporting. The document is primarily a certification letter and does not contain the actual financial statements or detailed financial data itself. It is also relatively short (4550 characters). According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than the actual Annual Report (10-K) or Management Discussion & Analysis (MDA).
2024-06-26 English
Annual MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management’s Discussion & Analysis' (MD&A) for the financial year ended March 31, 2024, and includes detailed sections such as company overview, financial highlights, discussion of operations, liquidity, risk factors, and reconciliations of non-GAAP measures. It references audited consolidated financial statements prepared under IFRS and is approved by the board of directors. The content is comprehensive and includes substantive financial data and analysis, typical of a Management Discussion & Analysis report that accompanies annual financial statements. It is not merely an announcement or a certification, nor is it a transcript, presentation, or other filing type. Therefore, the appropriate classification is Management Reports (MDA).
2024-06-26 English
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 100% confidence The document is an Independent Auditor's Report for Medexus Pharmaceuticals Inc. covering consolidated financial statements for the years ended March 31, 2024 and 2023. It includes detailed audit opinions, key audit matters, and descriptions of the audit process and responsibilities. The content is focused on the audit of the annual consolidated financial statements, including financial position, income, cash flows, and notes, which aligns with an Audit Report. The document is not the full Annual Report (10-K) as it does not include management discussion and analysis or other sections typical of a full annual report, but it is a standalone audit report. The length (15,000 characters) and detailed audit content confirm it is not a brief announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2024
2024-06-26 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.